Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
0.0876 x 5 0.0980 x 5
Post-market by (Cboe BZX)
0.0949 -0.0228 (-19.37%) 04/04/25 [NYSE Arca]
0.0876 x 5 0.0980 x 5
Post-market 0.0949 unch (unch) 20:00 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.0633
Day High
0.1179
Open 0.1120
Previous Close 0.1177 0.1177
Volume 2,305,500 2,305,500
Avg Vol 494,380 494,380
Stochastic %K 28.81% 28.81%
Weighted Alpha -81.33 -81.33
5-Day Change -0.0261 (-21.57%) -0.0261 (-21.57%)
52-Week Range 0.0633 - 0.6200 0.0633 - 0.6200
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,860
  • Shares Outstanding, K 72,290
  • Annual Sales, $ 170 K
  • Annual Income, $ -17,320 K
  • EBIT $ -20 M
  • EBITDA $ -19 M
  • 60-Month Beta 0.76
  • Price/Sales 50.05
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings $-0.10 on 03/27/25
  • Next Earnings Date 05/15/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0633 +49.92%
on 04/04/25
Period Open: 0.1234
0.1420 -33.17%
on 03/21/25
-0.0285 (-23.10%)
since 03/04/25
3-Month
0.0633 +49.92%
on 04/04/25
Period Open: 0.2335
0.2540 -62.64%
on 01/07/25
-0.1386 (-59.36%)
since 01/03/25
52-Week
0.0633 +49.92%
on 04/04/25
Period Open: 0.5298
0.6200 -84.69%
on 04/11/24
-0.4349 (-82.09%)
since 04/04/24

Most Recent Stories

More News
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

AIM : 0.0949 (-19.37%)
AIMI : 0.0360 (+7.46%)
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

AIM : 0.0949 (-19.37%)
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AIM : 0.0949 (-19.37%)
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AIM : 0.0949 (-19.37%)
Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

- Access video webcasts from all participating companies here

AIM : 0.0949 (-19.37%)
SONN : 1.2850 (-1.15%)
MBRX : 1.0500 (+10.50%)
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

TLSA : 1.1600 (+2.65%)
AIM : 0.0949 (-19.37%)
PEPG : 1.6200 (+6.58%)
AEON : 0.4050 (+1.25%)
MBRX : 1.0500 (+10.50%)
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM : 0.0949 (-19.37%)
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AIM : 0.0949 (-19.37%)
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

AIM : 0.0949 (-19.37%)
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

AIM : 0.0949 (-19.37%)

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 0.1754
2nd Resistance Point 0.1466
1st Resistance Point 0.1208
Last Price 0.0949
1st Support Level 0.0662
2nd Support Level 0.0374
3rd Support Level 0.0116

See More

52-Week High 0.6200
Fibonacci 61.8% 0.4073
Fibonacci 50% 0.3417
Fibonacci 38.2% 0.2760
Last Price 0.0949
52-Week Low 0.0633

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro